openPR Logo
Press release

Europe Parkinson’s Disease Drug Pipeline Analysis

06-30-2017 09:27 AM CET | Health & Medicine

Press release from: PNS Pharma

Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that with ageing population, its prevalence would grow significantly.

One of the major drivers of the Parkinson’s drugs market in the Europe is the rising uptake of key current brands along with the launch of three new therapies which would help sustain the Parkinson’s disease market through 2022. However, growing competition from generics would continue to restrain the market in the future. Consequently, owing to competitive forces, the total sales of therapies used to treat the disease would remain relatively flat over the next decade.

Download Report:

http://www.pnspharma.com/buy-report.php?reporttitle=Europe-Parkinson-Disease-Drug-Pipeline-Analysis

“Europe Parkinson’s Disease Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Parkinson’s disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the European Parkinson’s Disease drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Europe Parkinson’s Disease Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes

Europe Parkinson’s Disease Drug Pipeline by Clinical Phase:

• Research: 12

• Clinical: 26

• Phase-I: 14

• Phase-I/II: 2

• Phase-II: 6

• Phase-II/III: 1

• Phase-III: 3

• Preregistration: 1

• Marketed: 1

For Report Sample Contact: rajesh@pnspharma.com or :Visit :
https://www.pnspharma.com

Recent Publication

* Global Peptide Therapeutics Market & Clinical Trials Insight
* Global Orphan Drug Clinical Pipeline Insight 2022

PNS Pharma is a pioneer in offering exclusive research reports for the pharmaceuticals industry. PNS Pharma offers Syndicated Research Reports on Drug Pipeline and Company Pipeline Analysis. These reports include comprehensive information related to the development of various drugs across clinical pipeline. Further, the reports include details on the originator, Owner, License, Chemical Formula, Patent Information, Phase of development, and Phase of development by country for each specific drug. The reports on company pipeline include all the drugs developed by particular companies across different therapeutic segments and phases and in different countries.

Rajesh Arora
rajesh@pnspharma.com
PNS Pharma
8-9, Ansal Building
Dr. Mukherjee Nagar
Delhi, India

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Europe Parkinson’s Disease Drug Pipeline Analysis here

News-ID: 603379 • Views:

More Releases from PNS Pharma

Global Gene Therapy Market Opportunity By Clinical Trials Pipeline sales Kymriah …
"Global Gene Therapy Market Opportunity & Clinical Trials Insight 2026" Report Highlight: o Global Gene Therapy Market Opportunity: > US$ 8 Billion o Global Gene Therapy Clinical Pipeline: > 1000 Therapies In Clinical Trials o Commercially Available Gene Therapies: 11 o USA Dominates Global Gene Therapy Pipeline: > 500 Therapies In Clinical Trials o Cancer Accounts For 50% of Global Gene Therapy Trials Download Report: https://www.pnspharma.com/buy-report.php?reporttitle=Global-Gene-Therapy-Market-Opportunity-%26-Clinical-Trials-Insight-2026 Over the years, gene therapy has been highly responsible for decreasing the mortality rate
Global Orphan Drug Market Clinical Trials Pipeline Report Market Study 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Rare Disease Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria
Global Orphan Drug Market Opportunity To Surpass US$ 300 Billion By 2026
"Global Orphan Drug Clinical Trials, Patent & Guidelines Insight 2026" Report Highlights: o Global Orphan Drug Market Opportunity: US$ 300 Billion o US Dominates Global Orphan Drug Market: 50% Market Share o US Orphan Drug Opportunity To Surpass: US$ 150 Billion o Global Orphan Drug Clinical Insight: More Than 900 Drugs o Clinical Insight on Marketed Orphan Drugs: More Than 400 Drugs o Oncology To Dominate Orphan Drug Development: 35% Share o FDA & EMA Regulations For Orphan Drugs o Orphan Drug Designation Criteria

All 5 Releases


More Releases for Parkinson’s

Parkinson’s Disease Therapeutics Market 2021 | Detailed Report
Global Parkinson’s Disease Therapeutics Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and
Parkinson’s Disease Treatment Market 2021 | Detailed Report
Parkinson’s Disease Treatment Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Parkinsons Disease Treatment Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5024082 The report provides a comprehensive analysis of company profiles listed below: - Teva - Roche - Prothena - Acorda
Parkinson’s disease Therapeutics Parkinson’s disease Therapeutics Market to …
This report studies the global Parkinson's Disease Therapeutics market, analyzes and researches the Parkinson's Disease Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GSK Novartis Boehringer Ingelheim Teva Pharmaceutical Abbvie ….. Ask for sample copy @ https://www.researchtrades.com/request-sample/1199125 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, Parkinson's Disease Therapeutics can be split into Medications Therapeutics Medical Devices Therapeutics Buy
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,
New Education Options for Parkinson’s Caregivers
(4/30/2012- Gilbert, Ariz.) When a loved one is diagnosed with Parkinson’s Disease (PD), it becomes clear that Parkinson’s is a life- changing experience for the entire family — particularly for the primary care provider, who is most often a spouse, child or parent. Family caregivers may not think of themselves as a care providers or recognize their new caregiving tasks. As family members begin helping with doctor visits, taking over financial